Health Care
Biotech and Pharmaceuticals
featured
CNBC’s David Faber reports that Japanese drug company Takeda is increasing its proposal for Shire. » Read More
By: Angelica LaVito
J&J has added surgical products and a contact subscription service to its lineup of Acuvue contact lenses. » Read More |
By: Angelica LaVito
Drug manufacturers are using several schemes to "hamstring biosimilar competition," and FDA Commissioner Scott Gottlieb worries pharmacy benefit managers have been "complacent participants" in them. » Read More |
By: David Faber, Tae Kim
Allergan will not bid for Shire, according to sources close to the company. » Read More |
More
Jim Cramer hears from Revance Therapeutics co-founder, President and CEO Dan Browne about his biotechnology therapy that competes with Allergan's Botox.
Epidiolex would be the first drug on the market derived from the cannabis plant.
-
CNBC’s David Faber reports that pharma company Allergan will not follow through with a big on Shire, according to sources.
Allergan in talks to acquire Shire, competing against Takeda Pharmaceutical.
Takeda is in negotiations with Shire to acquire the London company after an unsuccessful $61 billion bid.
Opioid prescriptions are on the decline in the U.S., according to a new report from the Iqvia Institute. But experts say the number is still too high.
BenevolentAI said the latest round of funding will help it scale drug development and its AI platform.
Jim Cramer clarifies what money managers are expecting from tech giant IBM in order for the stock to be successful.
-
Jim Cramer clarifies what money managers are expecting from tech giant IBM in order for the stock to be successful.
"I'm not on board with just about anything that he does," Gov. Matt Bevin said of Kentucky Attorney General Andy Beshear.
Kentucky's attorney general sued Johnson & Johnson, accusing the pharmaceutical manufacturer of devising a deceptive marketing scheme that mischaracterized the risk of opioid abuse and addiction.
Shkreli had asked for a minimum security camp to complete his seven-year sentence for defrauding hedge-fund investors and manipulating the stock of the drug company Retrophin.
Shire, the $47 billion rare disease drugmaker being stalked by Japan's Takeda Pharmaceutical, faces fresh criticism over its executive pay policy from a leading investor advisory group.
The diversified healthcare company's quarterly profit and sales were helped by growth across its businesses and device launches.
Epic Products recalled its Euphoric supplements for male sexual enhancement after the FDA found they contained prescription drugs, the Kansas City Business Journal reports.
Johnson & Johnson shares rise in the premarket after first-quarter results exceeded expectations on earnings and revenue.
Contact Biotech and Pharma
-
CNBC NEWSLETTERS
Get the best of CNBC in your inbox
Get these newsletters delivered to your inbox, and more info about about our products and service. Privacy Policy.▲Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals.
Bertha Coombs is a general assignment reporter for CNBC, covering financial markets and business news stories.
